纵横研报
Tag

#rare disease

03Reports
JAZZ.US logo
·制药 ·内部研究

Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act

Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.

JAZZ.US Jazz Pharmaceuticals plc #Zanidatamab#Ziihera#Xywav#Rare Disease#Oncology#Specialty Pharma
Hold
·制药 ·内部研究

Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent

Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.

SAN.PA Sanofi SA #Dupixent#immunology#vaccines#rare disease#patent cliff#pure-play biopharma
Hold
BMRN.US logo
·生物医药·罕见病 ·内部研究

BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition

BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.

BMRN.US BioMarin Pharmaceutical Inc. #rare disease#VOXZOGO#enzyme therapy#Amicus#achondroplasia#rare-disease biopharma
Hold